Nurix Therapeutics (NASDAQ:NRIX) Stock: Insider Houte Hans Van Sells 4,769 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Hans van Houte sold 4,769 shares of Nurix Therapeutics stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $15.63, for a total transaction of $74,539.47. Following the sale, the chief financial officer directly owned 42,745 shares of the company’s stock, valued at $668,104.35. This represents a 10.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Houte Hans Van also recently made the following trade(s):

• On Friday, October 30th, Hans van Houte sold 2,834 shares of Nurix Therapeutics stock. The stock was sold at an average price of $26.28, for a total transaction of $74,477.52.

Nurix Therapeutics Stock Down 7.0%

NRIX opened at $14.84 on Friday. The stock has a market cap of $1.62 billion, a PE ratio of 6.42 and a beta of 1.80. Nurix Therapeutics, Inc. has a 52 week low of $11.67 and a 52 week high of $28.23. The business’s fifty day simple moving average is $24.49 and its 200 day simple moving average is $20.23.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Tuesday, October 13th. The company reported $4.73 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $5.33. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. The business had revenue of $673.06 million for the quarter, compared to the consensus estimate of $24.35 million. As a group, equities analysts anticipate that Nurix Therapeutics, Inc. will post 1.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on NRIX shares. Oppenheimer boosted their target price on Nurix Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 13th. Stifel Nicolaus set a $41.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, October 13th. Truist Financial reduced their price target on shares of Nurix Therapeutics from $34.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, October 13th. Mizuho lifted their price target on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Morgan Stanley boosted their price objective on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Fourteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $34.43.

Key Headlines Impacting Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix plans to present new and updated Phase 1a/1b data on bexobrutideg (NX-5948), its investigational BTK degrader for relapsed or refractory CLL/SLL, at the ASH annual meeting. The presentation may provide investors with fresh information on a key pipeline program, though the announcement does not disclose the results. Company announcement
• Neutral Sentiment: CFO Hans van Houte sold 4,769 shares under a pre-arranged Rule 10b5-1 plan. The sale reduced his holdings by about 10%, but the planned nature of the transaction makes it less clearly a signal of a change in his outlook. Insider sale report
• Negative Sentiment: Sanofi discontinued development of SAR448272, a STAT6 degrader licensed from Nurix. The loss of a partnered program is the clearest near-term negative catalyst for NRIX; reporting indicates the decision was not related to the STAT6 target itself. BioSpace report
• Negative Sentiment: Wells Fargo lowered its price target from $25 to $20, although it retained an “overweight” rating. The cut reflects reduced expectations, even as the rating signals continued optimism. Report on the price-target change

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of NRIX. GAMMA Investing LLC increased its stake in shares of Nurix Therapeutics by 95.4% in the third quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock worth $30,000 after buying an additional 620 shares during the period. Nykredit A S bought a new stake in Nurix Therapeutics during the 2nd quarter valued at $32,000. Integrated Wealth Concepts LLC purchased a new stake in Nurix Therapeutics during the 2nd quarter valued at $33,000. Fifth Third Bancorp boosted its position in Nurix Therapeutics by 613.8% during the 3rd quarter. Fifth Third Bancorp now owns 1,556 shares of the company’s stock valued at $37,000 after buying an additional 1,338 shares during the period. Finally, KBC Group NV purchased a new stake in Nurix Therapeutics during the 1st quarter valued at $34,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.

The company’s pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton’s tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.